FindTrial
Sign In

rivogenlecleucel

BIOLOGICAL5 trials

Sponsors

Bellicum Pharmaceuticals, Fred Hutchinson Cancer Center

Conditions

Acute Bilineal LeukemiaAcute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAnemia, AplasticAnemia, Sickle CellCytopeniaDiamond Blackfan AnemiaFanconi Anemia

Phase 1

Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT
WithdrawnNCT02786485
Bellicum PharmaceuticalsLeukemia, Lymphomas, Multiple Myeloma +2
Start: 2016-05-31End: 2018-12-31Updated: 2020-10-05
Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study
TerminatedNCT03733249
Bellicum PharmaceuticalsAcute Lymphoblastic Leukemia, Anemia, Aplastic, Anemia, Sickle Cell +9
Start: 2017-01-31End: 2023-04-14Updated: 2023-09-26
Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant
WithdrawnNCT03807063
Fred Hutchinson Cancer CenterAcute Bilineal Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable +9
Start: 2020-01-02End: 2021-12-31Updated: 2020-08-14

Phase 2

Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS
TerminatedNCT03699475
Bellicum PharmaceuticalsAcute Myeloid Leukemia, Myelodysplastic Syndromes
Start: 2018-12-27End: 2019-07-23Updated: 2023-09-29

Unknown Phase

BPX-501 T Cells Infused Post Stem Cell Transplant in Pediatrics With Non-Malignant Disorders Ineligible for BPU004 Study
NCT03639844
Bellicum PharmaceuticalsHurler Syndrome, Inborn Errors of Metabolism, Inherited Metabolic Disorder +2
Updated: 2020-10-05